Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Li2WO4 in preparing medicine

A technology of lithium tungstate and drugs, which is applied in the application field of lithium tungstate in pharmaceuticals, can solve the problems that there are no reports or patent applications for treatment-related diseases, and achieve the improvement of neurodegenerative diseases, inhibition of hyperphosphorylation, inhibition of active effect

Inactive Publication Date: 2007-09-19
JINAN UNIVERSITY
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Through literature search, it is found that lithium tungstate is currently limited to the application in the chemical industry, and there is no report or patent application for the treatment of related diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: The role of lithium tungstate in promoting the growth of neonatal mouse cerebral cortex neurons

[0022] As shown in Table 1-2, compared with the vehicle control group, the low concentration lithium tungstate group had no significant difference in the total number of processes, the length of processes, and the number of neurons with processes; the medium concentration lithium tungstate group and the high concentration tungstic acid Compared with the vehicle control group, the total number of processes, the length of processes, and the number of neurons with processes in the lithium group were significantly increased, and the effect of the high-concentration lithium tungstate group was significant. And the effect is better than lithium chloride group, sodium tungstate group and lithium chloride+sodium tungstate group.

[0023] group

[0024] Compared with the vehicle control group: * P** P<0.01

[0025] group

[0026] Compared with the ve...

Embodiment 2

[0027] Example 2: Lithium tungstate reduces Aβ secreted by M146L cells 42 content

[0028]The M146L cell line is a CHO cell transfected with APP and mutant PS-1 genes of human AD patients. Quantitative detection of Aβ by ELISA 42 output. As shown in Table 3: low doses of lithium tungstate have no effect on the production of Aβ42, medium and high doses of lithium tungstate can significantly reduce the production of Aβ42, especially the inhibition rate of the high dose group exceeds 70%, showing a good dose effect relation. And the effect is better than lithium chloride group, sodium tungstate group and lithium chloride+sodium tungstate group.

[0029] group

[0030] Compared with the vehicle control group: * P** P<0.01

Embodiment 3

[0031] Example 3: Lithium tungstate reduces Aβ in model mice injected with streptozotocin 1-40 , Aβ 1-42 content

[0032] Streptozotocin (STZ) is a nitrosourea derivative that can selectively destroy islet cells in the periphery, cause glucose metabolism disorders, and lead to diabetes; in the center, it can block insulin receptor autophosphorylation and intrinsic Tyrosine kinase activity, resulting in impaired insulin signaling.

[0033] Select 20 adult SD rats and divide them into 5 groups: normal control group, solvent control group, low-, medium- and high-dose lithium tungstate groups. The solvent control group and the lithium tungstate low, medium and high dose groups were injected with STZ 10 μl (3 mg / kg) into the bilateral lateral ventricles with a stereotaxic apparatus, and the injection was repeated on the third day. The normal control group was replaced by STZ with an equal amount of normal saline as described above. One week after modeling, the low-, medium-, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of tungstate lithium for preparing a medicine, in particular an application for preparing drug for treating neurodegenerative disease, neuropathy caused by diabetes, and cerebral ischemia including cerebral dysfunction. Both of activity of anion and cation of the tungstate lithium can perform synergistic reaction to inhibit activity of a GSK-3 much better. By inhibiting activity of a GSK-3 alpha, generation of the A beta is reduced to decrease SP; by inhibiting activity of a GSK-3 beta, hyperphosphorylation of tau protein is inhibitted to reduce NFT. Thereby, survival and wound repair of neurocyte are promoted even in a state of ischemia and anoxia to improve learning and memory dysfunction by increasing content of BDNF in cortical neurons.

Description

technical field [0001] The invention relates to the application of lithium tungstate as an active ingredient in medicines for treating neurodegenerative diseases, treating neuropathy caused by diabetes, and treating cerebral ischemia (including brain dysfunction) and related diseases. Background technique [0002] Alzheimer's disease (Alzheimer's disease, AD), also known as senile dementia, is a clinical feature of progressive memory loss, cognitive impairment and personality changes, with extracellular senile plaques (senile plaques) appearing in the cerebral cortex and hippocampus. Plaque, SP), intracellular neurofibrillary tangles (neurofibrillary tangles, NFT) and loss of cholinergic neurons are pathologically characterized neurodegenerative diseases. [0003] SP is slightly spherical, and its main component is β-amyloid protein (amyloidβ-protein, Aβ). The newly produced Aβ is soluble, not only has no neurotoxicity, but also has a certain neurotrophic effect. However, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/00A61P25/28
Inventor 罗焕敏翁文
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com